Overland Pharmaceuticals
Yi-Shin Lai has a strong background in the field of cell engineering and product development. They are currently working as the Director of Cell Engineering and Product Development at Overland Pharmaceuticals since 2023. Prior to this, they held various roles at Fate Therapeutics Inc, including Associate Director, Principal Scientist, Senior Scientist, and Scientist. Yi-Shin Lai also worked as a Research Laboratory Manager at UC San Diego in the Dan Kaufman Lab. They started their career as a Postdoctoral Researcher at the University of Alabama at Birmingham in 2012.
Yi-Shin Lai obtained a Doctor of Philosophy (PhD) degree in Biochemistry and Molecular Genetics from the University of Alabama at Birmingham. This degree was achieved between the years 2004 and 2012.
This person is not in any offices
Overland Pharmaceuticals
Founded in 2020, Overland Pharmaceuticals is establishing a leading cross-border platform company focused on advanced modalities through strategic partnering and in-house R&D. Overland is seeded by Hillhouse Capital with access to global innovation and China biopharma ecosystem. Overland is building an initial oncology portfolio of first-in-class ADC and allogeneic cell therapy programs for greater China and Asia through partnering with established biotechs. Through formative R&D partnerships and in-house technology platforms, Overland will move forward the development and commercialization of the most promising advances in medicine.